Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 25,000 Shares of Company Stock

Posted by Stanley Muller on Nov 4th, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Beth Hecht sold 25,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider owned 1,086,130 shares in the company, valued at approximately $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

On Thursday, October 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total value of $156,827.06.
On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total value of $141,494.34.

Xeris Biopharma Trading Up 1.1%

XERS stock traded up $0.11 during midday trading on Wednesday, reaching $10.46. The company’s stock had a trading volume of 3,142,009 shares, compared to its average volume of 2,030,196. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The stock has a fifty day simple moving average of $9.37 and a two-hundred day simple moving average of $7.54. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $11.41. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -95.09 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, equities research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of XERS. BlackRock Inc. purchased a new position in Xeris Biopharma in the second quarter valued at about $115,042,000. Legal & General Group Plc bought a new position in Xeris Biopharma in the second quarter worth about $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Xeris Biopharma during the second quarter valued at about $14,316,000. Bank of America Corp DE purchased a new stake in shares of Xeris Biopharma during the second quarter valued at about $11,065,000. Finally, Vilga Financial Planning LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter valued at about $10,134,000. Institutional investors own 42.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Barclays increased their price objective on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners upped their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.20.

Get Our Latest Stock Report on Xeris Biopharma

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.